Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch
Resource Download


Catalog No. T1615Cas No. 138402-11-6
Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker. The mechanism of action of irbesartan is as an Angiotensin 2 Receptor Antagonist.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePrice/USDAvailabilityQuantity
10 mg$48In Stock
25 mg$58In Stock
50 mg$90In Stock
100 mg$150In Stock
200 mg$189In Stock
500 mg$217In Stock
1 mL x 10 mM (in DMSO)$47In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Irbesartan"

Product Introduction

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker. The mechanism of action of irbesartan is as an Angiotensin 2 Receptor Antagonist.
In vitro
Administering 7 mg/kg of Irbesartan daily to rats with congestive heart failure induced by lily alkaloid significantly inhibited skeletal muscle cell apoptosis and intramuscular atrophy. This effect is associated with a decrease in TNFα levels and is attributed to AT1 receptor blockade. Oral administration of 1 mg/kg Irbesartan in conscious rats with normal blood pressure reduced angiotensin II-induced hypertension, exhibiting effects similar to losartan treatment. However, its efficacy in normotensive monkeys was significantly higher than that of 10 mg/kg losartan.
In vivo
At a concentration of 10 μM, Irbesartan inhibits the increase in mRNA and protein levels of integrins αv, β1, β3, and β5, osteopontin, and α-actinin in rat cardiac fibroblasts induced by angiotensin II, resulting in reduced cell adhesion to the extracellular matrix (ECM) proteins. Additionally, Irbesartan significantly induces the expression of the adipogenic marker gene, fatty acid-binding protein 2 (aP2), in 3T3-L1 cells in a concentration-dependent manner, with an EC50 of 3.5 μM and inducing effects being 3.3 times stronger at 10 μM. Also, 10 μM Irbesartan substantially induces peroxisome proliferator-activated receptor-γ transcriptional activity by 3.4 times, independent of its AT1 receptor antagonist action. Pre-treatment with 10 μM Irbesartan in rat vascular smooth muscle cells reduces angiotensin II-induced apoptosis by inhibiting angiotensin II internalization, demonstrating concentration dependency. Irbesartan competes with angiotensin II for binding to the AT1 receptor subtype with an IC50 of 1.3 nM and exhibits 10 times higher efficacy than Losartan in antagonizing AII-induced spasms in rabbit aortic rings, with IC50 values of 4 nM compared to Losartan's 14 nM and 25 nM, respectively.
AliasSR-47436, BMS-186295
Chemical Properties
Molecular Weight428.53
Cas No.138402-11-6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 25 mg/mL (58.34 mM)
Solution Preparation Table
1 mM2.3336 mL11.6678 mL23.3356 mL116.6779 mL
5 mM0.4667 mL2.3336 mL4.6671 mL23.3356 mL
10 mM0.2334 mL1.1668 mL2.3336 mL11.6678 mL
20 mM0.1167 mL0.5834 mL1.1668 mL5.8339 mL
50 mM0.0467 mL0.2334 mL0.4667 mL2.3336 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg,each TargetMol | Animal experiments animal weighs 20 g, and the dosage volume is 100 μL. A total of TargetMol | Animal experiments 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL.
Mother liquor preparation method: 2 mg of drug dissolved in 50 μLDMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μLDMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μLTween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify.
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.